Heron Therapeutics | HRTX - Cost Of Sales


Heron Therapeutics reported $11.12M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
ALKERMES USD 120.7M 47.44M Jun/2026
Alnylam Pharmaceuticals USD 298.45M 87.33M Jun/2026
Amarin USD 26.05M 1.41M Dec/2025
ANI Pharmaceuticals USD 119.8M 5.3M Jun/2026
Anika Therapeutics USD 11.44M 797K Dec/2025
Eisai JPY 51.09B 926M Jun/2026
Emergent BioSolutions USD 381.2M 226.1M Jun/2023
GlaxoSmithKline GBP 2.07B 192M Jun/2026
Heron Therapeutics USD 11.12M 795K Dec/2025
Insmed USD 69.29M 19.79M Jun/2026
Ligand Pharmaceuticals USD 11.31M 59K Jun/2026
Merck USD 3.14B 200M Jun/2026
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neurocrine Biosciences USD 39.4M 25.6M Jun/2026
Omeros USD 33.16M 18.52M Jun/2024
Pacira USD 58.49M 7.75M Jun/2026
Regeneron Pharmaceuticals USD 576.5M 92.9M Jun/2026
Roche Holding CHF 7.85B 630M Jun/2026
Sangamo BioSciences 2.42M 1.11M Jun/2024
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Veracyte USD 42.19M 3.7M Jun/2026
Vertex Pharmaceuticals USD 489.2M 96.4M Jun/2026